03/23/2022
Anapharm Bioanalytics acquires a new high sensitivity equipment: SCIEX Triple Quad 6500+ system
Anapharm Bioanalytics’ small molecule division continues to expand its capabilities with the acquisition of a new LC-MS/MS equipment tailored for method development and validation of high sensitivity assays. The new instrument increases our capabilities for peptide chemistry as well as for orally inhaled drugs such as for example Glycopyrronium; Indacaterol, Fluticasone, Salmeterol, Budesonide, Tiotropium, etc. in biological fluids.
The Triple Quad 6500+ system features multi-component IonDrive Technology including the IonDrive High Energy Detector+ that delivers revolutionary sensitivity, speed, and performance for the most challenging methods.
MORE NEWS
Peptides Series: Understanding Therapeutic Peptides
Therapeutic peptides are transforming modern medicine thanks to their unique advantages over traditional drug therapies. Their molecular structure and biological properties allow them to achieve effects like natural molecules in the body, enabling targeted action with fewer risks of off-target effects.
The visit of the Mayor of Barcelona, Jaume Collboni, to Anapharm Bioanalytics
Last Friday, January 10th 2025, we had the honor of welcoming the Mayor of Barcelona, Jaume Collboni, to our facilities. His visit was a special opportunity for us to showcase the work we do at Anapharm Bioanalytics and to reaffirm our commitment to innovation in the field of bioanalysis.
Overcoming Matrix Effects in the Analysis of Lipophilic Compounds
At the 10th EBF Young Scientist Symposium, we highlighted the complexities of analysing Fucoxanthin derivatives and demonstrated how innovative approaches, such as 2D Chromatography, can overcome these obstacles.